RecruitingPhase 2NCT06839144

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tel-Aviv Sourasky Medical Center
Principal Investigator
Nadav Michaan, Prof.
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Intervention
Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)(drug)
Enrollment
60 target
Eligibility
20-85 years · FEMALE
Timeline
20252026

Study locations (2)

Collaborators

National Cancer Institute (NCI) · The Chaim Sheba Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06839144 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials